Company identity
Company number 04202562
Company profile
UK company 04202562, incorporated on 20 April 2001.
Locate Bio Defining the future of Orthobiologics
Locate Bio Limited is a UK company with status active founded in 2001 based in East Midlands.
Company number 04202562
Updated 07 Jul 2026 09:49
Financial period: 1 Nov 2023 to 31 Oct 2024
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
1 Oct 2020 to 30 Jun 2021
The UK has invested for many years in the science of regenerative medicine. This field is delivering on its promise to repair human tissues. Given the UK's strong position in the science that underpins this area we should also aim to develop a world-leading industry that exports regenerative medicines across the world. This project aims to demonstrate tha...
1 Aug 2017 to 31 Jul 2019
This project aims to develop a new surgical product that will cure diabetic patients of a specific type of severe back pain. When the backbone is damaged or deteriorates due to disease and aging, chronic pain can result due to a loss of elasticity and protection in the disc structure. One clincial treatment that is offered is to fuse the affected segments...
1 Feb 2016 to 31 Mar 2017
Emerging cell therapies have vast potential in the treatment of currently incurable diseases; the potential market for cell-based therapies being over 100 million patients in the US alone. Some of the main targets include heart disease, diabetes, neurodegenerative diseases, musculoskeletal disorders, spinal cord injury, stroke, autoimmune diseases and tra...
1 Jan 2014 to 31 Dec 2016
Our rapid increase in the understanding of the biology underlying many bodily repair processes has led to new perspectives in the design and use of materials to address disease or injury. For restorative stem cells to fully participate in tissue regeneration they need to be packaged in a delivery material that provides an optimal environment for them to f...
1 Aug 2013 to 30 Nov 2013
Emerging cell therapies have vast potential in the treatment of currently incurable diseases; the potential market for cell-based therapies is over 100 million patients in the US alone. Some of the main targets include heart disease, diabetes, neurodegenerative diseases, musculoskeletal disorders, spinal cord injury, stroke, autoimmune diseases and trauma...
1 Sep 2012 to 30 Nov 2014
Awaiting Public Summary
1 Jul 2010 to 31 Mar 2011
Awaiting Public Summary
1 May 2008 to 30 Apr 2011
Awaiting Public Summary
1 Jan 2005 to 30 Jun 2008
Awaiting Public Summary